Localization of A11-reactive oligomeric species in prion diseases

Histopathology

Volumn 62, Issue 7, 2013, Pages 994-1001

  Aidt, Frederik H ^a,b   Hasholt, Lis F ^b   Christiansen, Michael ^a   Laursen, Henning ^c  

^a STATENS SERUM INSTITUT   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c Rigshospitalet   (Denmark)

Author keywords

A11; Amyloid; Creutzfeldt Jakob disease; Immunohistochemistry; Neurodegeneration; Prion diseases; PrpSc proteins

Indexed keywords

AMYLOID OLIGOMER ANTIBODY A11; PRION PROTEIN; PROTEIN ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; AMYLOID PLAQUE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE MUTATION; GRANULAR CELL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LEUKOENCEPHALOPATHY; MALE; NERVE DEGENERATION; PRION DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN LOCALIZATION; SPORADIC CREUTZFELDT JAKOB DISEASE; WORLD HEALTH ORGANIZATION;

AGED; AGED, 80 AND OVER; CREUTZFELDT-JAKOB SYNDROME; FEMALE; GERSTMANN-STRAUSSLER-SCHEINKER DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; OLIGONUCLEOTIDES; PRION DISEASES; PROTEIN CONFORMATION; PROTEIN ISOFORMS; PRPC PROTEINS;

EID: 84877921931     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12097     Document Type: Article

References (52)

1. Prusiner SB. Novel proteinaceous infectious particles cause scrapie. Science 1982; 216; 136-144.
2. Pan KM, Baldwin M, Nguyen J et al. Conversion of alpha-helices into beta-sheets features in the formation of the scrapie prion proteins. Proc. Natl Acad. Sci. USA 1993; 90; 10962-10966.
3. Budka H, Aguzzi A, Brown P et al. Neuropathological diagnostic criteria for Creutzfeldt-Jakob disease (CJD) and other human spongiform encephalopathies (prion diseases). Brain Pathol. 1995; 5; 459-466.
4. Ma J, Lindquist S. Conversion of PrP to a self-perpetuating PrPSc-like conformation in the cytosol. Science 2002; 298; 1785-1788.
5. Caughey B. Interactions between prion protein isoforms: the kiss of death? Trends Biochem. Sci. 2001; 26; 235-242.
6. Asante EA, Linehan JM, Desbruslais M et al. BSE prions propagate as either variant CJD-like or sporadic CJD-like prion strains in transgenic mice expressing human prion protein. EMBO J. 2002; 21; 6358-6366.
7. Scott MR, Will R, Ironside J et al. Compelling transgenetic evidence for transmission of bovine spongiform encephalopathy prions to humans. Proc. Natl Acad. Sci. USA 1999; 96; 15137-15142.
8. Prusiner SB. Prion biology and disease. New York: Cold Spring Habor Laboratory Press, 2004.
9. Masters CL, Gajdusek DC, Gibbs CJ Jr. The familial occurrence of Creutzfeldt-Jakob disease and Alzheimer's disease. Brain 1981; 104; 535-558.
10. Will RG. Acquired prion disease: iatrogenic CJD, variant CJD, kuru. Br. Med. Bull. 2003; 66; 255-265.
11. Uversky VN. Mysterious oligomerization of the amyloidogenic proteins. FEBS J. 2010; 277; 2940-2953.
12. Yoshiike Y, Kayed R, Milton SC et al. Pore-forming proteins share structural and functional homology with amyloid oligomers. NeuroMol. Med. 2007; 9; 270-275.
13. Kayed R, Head E, Thompson JL et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 2003; 300; 486-489.
14. Kayed R, Sokolov Y, Edmonds B et al. Permeabilization of lipid bilayers is a common conformation-dependent activity of soluble amyloid oligomers in protein misfolding diseases. J. Biol. Chem. 2004; 279; 46363-46366.
15. Aguzzi A, Falsig J. Prion propagation, toxicity and degradation. Nat. Neurosci. 2012; 15; 936-939.
16. Caughey B, Lansbury PT. Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu. Rev. Neurosci. 2003; 26; 267-298.
17. Wu D, Zhang W, Luo Q et al. Copper(II) promotes the formation of soluble neurotoxic PrP oligomers in acidic environment. J. Cell. Biochem. 2010; 111; 627-633.
18. Kazlauskaite J, Young A, Gardner CE et al. An unusual soluble beta-turn-rich conformation of prion is involved in fibril formation and toxic to neuronal cells. Biochem. Biophys. Res. Commun. 2005; 328; 292-305.
19. Simoneau S, Rezaei H, Sales N et al. In vitro and in vivo neurotoxicity of prion protein oligomers. PLoS Pathog. 2007; 3; e125.
20. Shmerling D, Hegyi I, Fischer M et al. Expression of amino-terminally truncated PrP in the mouse leading to ataxia and specific cerebellar lesions. Cell 1998; 93; 203-214.
21. Sasaki K, Minaki H, Iwaki T. Development of oligomeric prion-protein aggregates in a mouse model of prion disease. J. Pathol. 2009; 219; 123-130.
22. Resenberger UK, Harmeier A, Woerner AC et al. The cellular prion protein mediates neurotoxic signalling of beta-sheet-rich conformers independent of prion replication. EMBO J. 2011; 30; 2057-2070.
23. Kristiansen M, Deriziotis P, Dimcheff DE et al. Disease-associated prion protein oligomers inhibit the 26S proteasome. Mol. Cell 2007; 26; 175-188.
24. Gubbels S, Bacci S, Laursen H et al. Description and analysis of 12 years of surveillance for Creutzfeldt-Jakob disease in Denmark, 1997 to 2008. Euro. Surveill. 2012; 17; Article 4; 1-9.
25. Halfmann R, Alberti S, Krishnan R et al. Opposing effects of glutamine and asparagine govern prion formation by intrinsically disordered proteins. Mol. Cell 2011; 43; 72-84.
26. Krishnan R, Goodman JL, Mukhopadhyay S et al. Conserved features of intermediates in amyloid assembly determine their benign or toxic states. Proc. Natl Acad. Sci. USA 2012; 109; 11172-11177.
27. Liberski PP, Sikorska B, Hauw JJ et al. Ultrastructural characteristics (or evaluation) of Creutzfeldt-Jakob disease and other human transmissible spongiform encephalopathies or prion diseases. Ultrastruct. Pathol. 2010; 34; 351-361.
28. Cobb NJ, Surewicz WK. Prion diseases and their biochemical mechanisms. Biochemistry 2009; 48; 2574-2585.
29. Wang F, Yin S, Wang X et al. Role of the highly conserved middle region of prion protein (PrP) in PrP-lipid interaction. Biochemistry 2010; 49; 8169-8176.
30. Barron RM, Campbell SL, King D et al. High titers of transmissible spongiform encephalopathy infectivity associated with extremely low levels of PrPSc in vivo. J. Biol. Chem. 2007; 282; 35878-35886.
31. Piccardo P, Manson JC, King D et al. Accumulation of prion protein in the brain that is not associated with transmissible disease. Proc. Natl Acad. Sci. USA 2007; 104; 4712-4717.
32. Tremblay P, Ball HL, Kaneko K et al. Mutant PrPSc conformers induced by a synthetic peptide and several prion strains. J. Virol. 2004; 78; 2088-2099.
33. Gambetti P. Human prion disease: how many are there? Clin. Neuropathol. 2012; 31; 233.
34. Magalhaes AC, Baron GS, Lee KS et al. Uptake and neuritic transport of scrapie prion protein coincident with infection of neuronal cells. J. Neurosci. 2005; 25; 5207-5216.
35. Silveira JR, Raymond GJ, Hughson AG et al. The most infectious prion protein particles. Nature 2005; 437; 257-261.
36. Caughey B, Baron GS, Chesebro B, Jeffrey M. Getting a grip on prions: oligomers, amyloids, and pathological membrane interactions. Annu. Rev. Biochem. 2009; 78; 177-204.
37. Solomon IH, Schepker JA, Harris DA. Prion neurotoxicity: insights from prion protein mutants. Curr. Issues Mol. Biol. 2010; 12; 51-61.
38. Chich JF, Chapuis C, Henry C et al. Vesicle permeabilization by purified soluble oligomers of prion protein: a comparative study of the interaction of oligomers and monomers with lipid membranes. J. Mol. Biol. 2010; 397; 1017-1030.
39. Bahadi R, Farrelly PV, Kenna BL et al. Channels formed with a mutant prion protein PrP(82-146) homologous to a 7-kDa fragment in diseased brain of GSS patients. Am. J. Physiol. Cell Physiol. 2003; 285; C862-C872.
40. Berest V, Rutkowski M, Rolka K et al. The prion peptide forms ion channels in planar lipid bilayers. Cell. Mol. Biol. Lett. 2003; 8; 353-362.
41. Thellung S, Corsaro A, Villa V et al. Human PrP90-231-induced cell death is associated with intracellular accumulation of insoluble and protease-resistant macroaggregates and lysosomal dysfunction. Cell Death Dis. 2011; 2; e138;1-10.
42. Paulis D, Maras B, Schinina ME et al. The pathological prion protein forms ionic conductance in lipid bilayer. Neurochem. Int. 2011; 59; 168-174.
43. Solomon IH, Huettner JE, Harris DA. Neurotoxic mutants of the prion protein induce spontaneous ionic currents in cultured cells. J. Biol. Chem. 2010; 285; 26719-26726.
44. Solomon IH, Biasini E, Harris DA. Ion channels induced by the prion protein: mediators of neurotoxicity. Prion 2012; 6; 40-45.
45. Sanghera N, Pinheiro TJ. Binding of prion protein to lipid membranes and implications for prion conversion. J. Mol. Biol. 2002; 315; 1241-1256.
46. Benilova I, Karran E, De Strooper B. The toxic Abeta oligomer and Alzheimer's disease: an emperor in need of clothes. Nat. Neurosci. 2012; 15; 349-357.
47. Demuro A, Mina E, Kayed R et al. Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers. J. Biol. Chem. 2005; 280; 17294-17300.
48. Kostka M, Hogen T, Danzer KM et al. Single particle characterization of iron-induced pore-forming alpha-synuclein oligomers. J. Biol. Chem. 2008; 283; 10992-11003.
49. Schmidt F, Levin J, Kamp F et al. Single-channel electrophysiology reveals a distinct and uniform pore complex formed by alpha-synuclein oligomers in lipid membranes. PLoS ONE 2012; 7; e42545.
50. Lal R, Lin H, Quist AP. Amyloid beta ion channel: 3D structure and relevance to amyloid channel paradigm. Biochim. Biophys. Acta 2007; 1768; 1966-1975.
51. Sokolov Y, Kozak JA, Kayed R et al. Soluble amyloid oligomers increase bilayer conductance by altering dielectric structure. J. Gen. Physiol. 2006; 128; 637-647.
52. Valincius G, Heinrich F, Budvytyte R et al. Soluble amyloid beta-oligomers affect dielectric membrane properties by bilayer insertion and domain formation: implications for cell toxicity. Biophys. J 2008; 95; 4845-4861.